The leukemias: A half-century of discovery

Journal of Clinical Oncology

Volumn 32, Issue 31, 2014, Pages 3463-3469

  Freireich, Emil J ^a   Wiernik, Peter H ^b   Steensma, David P ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Cancer Research Foundation of New York   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTHRACYCLINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BUSULFAN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; FOLIC ACID ANTAGONIST; METHOTREXATE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LEUKEMIA CELL LINE; LONG TERM SURVIVAL; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROMYELOCYTIC LEUKEMIA; REVIEW; TREATMENT OUTCOME; HISTORY; PUBLISHING; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEUKEMIA; PUBLISHING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84911489275     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.1034     Document Type: Review

References (105)

1. Nowell PC, Hungerford D: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497-1501, 1960
2. Drexler HG, Macleod RA: History of leukemia-lymphoma cell lines. Hum Cell 23:75-82, 2010
3. Fortier JM, Graubert TA: Murine models of human acute myeloid leukemia. Cancer Treat Res 145:183-196, 2010
4. Farber S, Diamond LK: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 238:787-793, 1948
5. Skipper HE, Thomson JR, Elion GB, et al: Observations on the anticancer activity of 6-mercaptopurine. Cancer Res 14:294-298, 1954
6. Wiltshaw E: The treatment of leukemia. N Engl J Med 270:570-572, 1964
7. Burchenal JH: Recent advances and perspectives in the chemotherapy of acute leukemia. Proc Natl Cancer Conf 5:651-657, 1964
8. Fishbein WN, Carbone PP, Freireich EJ, et al: Clinical trials of hydroxyurea in patients with cancer and leukemia. Clin Pharmacol Ther 5:574-580, 1964
9. Dimarco A, Gaetani M, Dorigotti L, et al: Daunomycin: A new antibiotic with antitumor activity. Cancer Chemother Rep 38:31-38, 1964
10. Freireich EJ: The road to the cure of acute lymphoblastic leukemia: A personal perspective. Oncology 54:265-269, 1997
11. Pui CH, Evans WE: A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 50:185-196, 2013
12. Grimwade D, Mistry AR, Solomon E, et al: Acute promyelocytic leukemia: A paradigm for differentiation therapy. Cancer Treat Res 145:219-235, 2010
13. Druker BJ: Perspectives on the development of imatinib and the future of cancer research. Nat Med 15:1149-1152, 2009
14. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7:441-453, 2007
15. Inaba H, Greaves M, Mullighan CG: Acute lymphoblastic leukaemia. Lancet 381:1943-1955, 2013
16. Badoux XC, Keating MJ, Wen S, et al: Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 31:584-591, 2013
17. Goldman JM: Chronic myeloid leukemia: A historical perspective. Semin Hematol 47:302-311, 2010
18. Wiernik PH: Lessons learned about treatment of the more common neoplasms from the study of acute leukemia. Cancer J Sci Am 2:356-359, 1996
19. Kampen KR: The discovery and early understanding of leukemia. Leuk Res 36:6-13, 2012
20. Piller G: Leukaemia: A brief historical review from ancient times to 1950. Br J Haematol 112:282-292, 2001
21. Neumann E: On the role of the bone marrow in blood formation. A contribution to the developmental history of the blood cells [in German]. Arch Heilkunde 10:68-102, 1869
22. Bizzozero G: On the hematopoietic function of the bone marrow [in Italian]. Gazzetta med ltal Lombard 46, 1868
23. Friedreich N: A new case of leukemia [in German]. Virchows Arch Pathol Anat 12:37-58, 1857
24. Ehrlich P: On the significance of neutrophil granulation [in German]. Charite Annales 12:288-295, 1887
25. Naegli O: On red bone marrow and myeloblasts [in German]. Dtsch Med Wochenschr 18:287-290, 1900
26. Parapia LA: Trepanning or trephines: A history of bone marrow biopsy. Br J Haematol 139:14-19, 2007
27. Beutler E: The treatment of acute leukemia: Past, present, and future. Leukemia 15:658-661, 2001
28. Freireich EJ: The history of leukemia therapy: A personal journey. Clin Lymphoma Myeloma Leuk 12:386-392, 2012
29. Lissauer H: Two cases of leukemia [in German]. Berliner Klinische Wochenschrift 2:403-404, 1865
30. Cutler EG, Bradford EH: Action of iron, cod liver oil, and arsenic on the globular richness of the blood. Am J Med Sci 75:74-84, 1970
31. Minot GR, Buckman TE, Isaacs R: Chronic myelogenous leukemia, age, incidence, duration and benefit derived from irradiation. JAMA 82:1489-1494, 1924
32. Wintrobe MM: Current views concerning the nature of management of leukemia and allied disorders. Am Pract Dig Treat 1:68-74, 1950
33. Mukherjee S: The Emperor of All Maladies. New York, NY, Scribner, 2010
34. DeVita VT Jr, Chu E: A history of cancer chemotherapy. Cancer Res 68:8643-8653, 2008
35. Frei E 3rd, Holland JF, Schneiderman MA, et al: A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 13:1126-1148, 1958
36. Frei E 3rd, Karon M, Levin RH, et al: The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26:642-656, 1965
37. George P, Hernandez K, Hustu O, et al: A study of "total therapy" of acute lymphocytic leukemia in children. J Pediatr 72:399-408, 1968
38. Möricke A, Zimmermann M, Reiter A, et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265-284, 2010
39. Schrappe M, Reiter A, Ludwig WD, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90-German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310-3322, 2000
40. Schultz KR, Bowman WP, Aledo A, et al: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 27:5175-5181, 2009
41. Leung W, Campana D, Yang J, et al: High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 118:223-230, 2011
42. Pui CH, Howard SC: Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 9:257-268, 2008
43. Möricke A, Reiter A, Zimmermann M, et al: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477-4489, 2008
44. Rowe JM, Buck G, Burnett AK, et al: Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial-MRC UKALL XII/ECOG E2993. Blood 106:3760-3767, 2005
45. Fielding AK, Rowe JM, Buck G, et al: UKALLXII/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123:843-850, 2014
46. Thomas DA, O'Brien S, Faderl S, et al: Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28:3880-3889, 2010
47. Sive JI, Buck G, Fielding A, et al: Outcomes in older adults with acute lymphoblastic leukaemia (ALL): Results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol 157:463-471, 2012
48. Wiernik PH, Dutcher JP, Paietta E, et al: Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: A nonanthracycline containing regimen. Leukemia 7:1236-1241, 1993
49. Foa R, Vitale A, Vignetti M, et al: Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 118:6521-6528, 2011
50. Aster JC, Pear WS, Blacklow SC: Notch signaling in leukemia. Annu Rev Pathol 3:587-613, 2008
51. Grupp SA, Kalos M, Barrett D, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518, 2013
52. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009
53. Ferrara F: New agents for acute myeloid leukemia: Is it time for targeted therapies? Expert Opin Investig Drugs 21:179-189, 2012
54. Rowley JD: Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 16:109-112, 1973
55. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976
56. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
57. Yates JW, Wallace HJ Jr, Ellison RR, et al: Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia Cancer Chemother Rep 57:485-488, 1973
58. Berman E, Heller G, Santorsa J, et al: Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 77:1666-1674, 1991
59. Wiernik PH, Banks PL, Case DC Jr, et al: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319, 1992
60. Wang J, Yang YG, Zhou M, et al: Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. PLoS One 8:e60699, 2013
61. Fernandez HF, Sun Z, Yao X, et al: Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-1259, 2009
62. Lee JH, Joo YD, Kim H, et al: A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 118:3832-3841, 2011
63. Teuffel O, Leibundgut K, Lehrnbecher T, et al: Anthracyclines during induction therapy in acute myeloid leukaemia: A systematic review and metaanalysis. Br J Haematol 161:192-203, 2013
64. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B N Engl J Med 331:896-903, 1994
65. Thomas ED, Buckner CD, Clift RA, et al: Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301:597-599, 1979
66. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349-2361, 2009
67. Burnett AK, Milligan D, Prentice AG, et al: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114-1124, 2007
68. Kantarjian HM, Thomas XG, Dmoszynska A, et al: Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670-2677, 2012
69. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569, 2010
70. Breitman TR, Collins SJ, Keene BR: Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 57:1000-1004, 1981
71. Breitman TR, Selonick SE, Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 77:2936-2940, 1980
72. Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988
73. Fenaux P, Le Deley MC, Castaigne S, et al: Effect of all transretinoic acid n newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial-European APL 91 Group. Blood 82:3241-3249, 1993
74. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028, 1997
75. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-4302, 2002
76. Gregory J, Kim H, Alonzo T, et al: Treatment of children with acute promyelocytic leukemia: Results of the first North American Intergroup trialNT0129. Pediatr Blood Cancer 53:1005-1010, 2009
77. Douer D, Zickl LN, Schiffer CA, et al: All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129. Leuk Res 37:795-801, 2013
78. Avvisati G, Lo-Coco F, Paoloni FP, et al: AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: Very long-term results and role of maintenance. Blood 117:4716-4725, 2011
79. Burnett AK, Hills RK, Grimwade D, et al: Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: Results of the MRC AML15 trial. Leukemia 27:843-851, 2013
80. Shen ZX, Chen GQ, Ni JH, et al: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360, 1997
81. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348, 1998
82. Niu C, Yan H, Yu T, et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315-3324, 1999
83. Gore SD, Gojo I, Sekeres MA, et al: Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 28:1047-1053, 2010
84. Powell BL, Moser B, Stock W, et al: Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751-3757, 2010
85. Lo-Coco F, Avvisati G, Vignetti M, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111-121, 2013
86. Chendamarai E, Balasubramanian P, George B, et al: Role of minima residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Blood 119:3413-3419, 2012
87. Cheng SH, Lau KM, Li CK, et al: Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction. PLoS One 8:e69467, 2013
88. Rossi G, Minervini MM, Melillo L, et al: Predictive role of minimal residua disease and log clearance in acute myeloid leukemia: A comparison between multiparameter flow cytometry and Wilm's tumor 1 levels. Ann Hematol 93 1149-1157, 2014
89. Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa stainng. Nature 243:290-293, 1973
90. Heisterkamp N, Stam K, Groffen J, et al: Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315:758-761, 1985
91. Kantarjian HM, Talpaz M: Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia. Semin Oncol 21:8-13, 1994
92. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
93. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
94. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
95. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003
96. Hehlmann R, Müller MC, Lauseker M, et al: Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-study IV. J Clin Oncol 32:415-423, 2014
97. Cortes JE, Kim DW, Pinilla-Ibarz J, et al: A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783-1796, 2013
98. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975
99. Bazargan A, Tam CS, Keating MJ: Predicting survival in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 12:393-403, 2012
100. Binet JL, Auquier A, Dighiero G, et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206, 1981
101. Keating MJ, Kantarjian H, O'Brien S, et al: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44-49, 1991
102. Wierda W, O'Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005
103. Foon KA, Mehta D, Lentzsch S, et al: Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood 119:3184-3185, 2012
104. Kristinsson SY, Dickman PW, Wilson WH, et al: Improved survival in chronic lymphocytic leukemia in the past decade: A population-based study including 11, 179 patients diagnosed between 1973-2003 in Sweden. Haematologica 94:1259-1265, 2009
105. Jones JA, Byrd JC: How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 123:1455-1460, 2014